Scientific Article
previous document  unige:9990  next document
add to browser collection

[Chirality and drugs]

Testa, Bernard
Reist, Marianne
Published in Annales pharmaceutiques françaises. 2000, vol. 58, no. 4, p. 239-246
Abstract The two enantiomers of a chiral drug may have vastly different pharmacodynamic and pharmacokinetic properties. As a result, the research and development of chiral drugs raises specific problems some of which are discussed here. Thus, various pharmacokinetic interactions may involve two enantiomers, as seen for example when one enantiomer inhibits the metabolism of the other and modifies its effects. A different situation occurs when a third compound stereoselectively inhibits the metabolism of one of the two enantiomers. Another problem examined here results from the lack of configurational stability of some chiral drugs, a little known phenomenon whose consequences can be of pharmacological or pharmaceutical significance depending on the rate of the reaction of racemization or epimerisation. In-depth investigations are needed before choosing between a eutomer or a racemate.
Keywords Drug TherapyPharmaceutical Preparations/*chemistryPharmacokineticsStereoisomerism
PMID: 10915971
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
(ISO format)
TESTA, Bernard, REIST, Marianne, CARRUPT, Pierre-Alain. [Chirality and drugs]. In: Annales pharmaceutiques françaises, 2000, vol. 58, n° 4, p. 239-246.

329 hits

0 download


Deposited on : 2010-08-06

Export document
Format :
Citation style :